(Paid Advertisement}

WillyWizard
Presents

PinkSheet:
MVSR

Points Of Interest

MVSR is not a pharmaceutical company per
se.  The believe is MVSR is better than most pharmaceutical companies
because they don’t actually manufacture the drugs but have contracts in
place to sell them.

MVSR has revenue sharing agreements in
place with PanGenex for Lipideme.  Another big agreement is for Mucotrol. 
More recently MVSR has signed exclusive distribution right for Albumax in
Italy.

MVSR=92s present status could even be
compared to Johnson & Johnson and their sales and marketing arrangement
with Closure Medical, the maker of Liquid Bandage.
Closure was a small-cap stock that in effect did with JNJ precisely what
MVSR is doing now with Cura Pharmaceutical and other manufacturers in the
industry.

THE END RESULT: JNJ buys out Closure Medical for $370 Million or $27 per
share!!!
We all know how important health care is. Drug manufacturer are developing
life saving drugs that need to get to the market as soon as possible.

Just think about it, if a drug company has
found a cure for AIDS, but doctors didn=92t know about this discovery, than
what good is the drug.

MVSR is making this possible with their expertise in marketing.

MVSR is a medical communications company dedicated to providing concise
and timely medical information to healthcare industry professionals. MVSR
exclusively serves the bioscience and pharmaceutical markets, offering
specialized medical marketing consulting, graphic design, web site
marketing strategy and market research.

MVSR has many exclusive deals with drug manufacturers to market their
products for nice cut of the profits from drug sales.

If you read though some of their latest press release, you will see that
MVSR is signing deals left and right!!

Some of the drugs that MVSR are marketing are in high demand, which means
huge profits for MVSR.

MVSR just reported this week, exclusive distribution rights in Italy for
Albumax. Albumax, a whey protein isolate formula, makes it easy for Kidney
disorder patients to reach their daily requirements of high quality
protein in their diet.

"Research we have conducted in Italy shows tremendous interest in Albumax,"
stated Dino Luzzi, CEO of Medivisor Inc. "In both the United States and
Italy, our sales and distribution network has strong customer
relationships, allowing us to leverage our existing distribution
capabilities. We intend to use Italy as a starting point to launch the
product throughout the rest of Europe."

That=92s just one example of MVSR current client.

We have all seen some of these pharmaceutical stocks double over night
with their block buster drugs. Imagine that MVSR was their marketing
partner, which means MVSR profits would skyrocket!!

Compare MVSR with PDII, which pretty much has the same business plan and
you will see MVSR is trading at a bargain.

PDII is currently trading at $8.10, while MVSR is trading at .30
 

The markets are very volatile right now
which makes it a potential for huge gains.  This includes MVSR.  Make sure
you watch it closely as it could make big swings in either directions.

Start your research on MVSR now, MVSR is
very volatile so watch it carefully.  Always do your own research as small
caps are inheritably risky.

MVSR is very similar to PDII which has
traded over $10 in the last 52wk weeks.  They both provide sales and
marketing services to biopharmaceutical and life sciences industries in
the US and Overseas.

The big advantage for MVSR is it’s price,
which is trading at a ridiculous low $0.30.

When Wall Street finds MVSR and makes the
comparison to PDII, MVSR could skyrocket!!

I think the point you should focus on with
MVSR is that they have numerous contracts in place with various
pharmaceutical companies.

MVSR’s most significant contract is for
Mucotrol. 

Mucotrol is FDA approved!!!  Let me tell
you what Murotrol treats and how it will affect MVSR.

Murotrol treats mucosistis.  It’s a lot
like a cold sore inside of the mouth.

Mucositis is an inflammation of mucous
membranes in the mouth. It usually appears as red, burn-like sores or as
ulcer-like sores throughout the mouth.

The National Cancer Institute estimates that approximately 300,000 cancer
patients in the US suffer from mucositis associated with cancer
treatments.

Mucotrol is a concentrated oral gel wafer formulation. When slowly
dissolved in the mouth, Mucotrol forms a coating on the oral mucosal
surface, resulting soothing oral lesions, including oral mucositis that
may be caused by chemotherapy or radiotherapy.

Mucotrol is formulated as a slow-dissolving
wafer for the convenience of the user. Unlike other products, no water is
required for the usage of this product.

MVSR is in charged with the sales and
marketing of Murotrol in the United States.  As you may already know the
companies that manufacture or sell pharmaceutical drugs make big bucks!!! 
Some drug companies charge multiple dollars for just one pill!!

Treating pain from illness and disease
generates $BILLIONS in sales for profit-rich Pharmaceutical and
Bio-science Companies every year. This is a huge market as it falls under
the behemoth category of pain management and pain relief.

Keep in mind Murotrol is just one of many
drugs that MVSR has under contract.  Another big one that MVSR is selling
is Albumax.

Albumax is a whey protein isolate formula
that makes it easy for kidney disorder patients to reach their daily
requirements of high quality protein in their diet.  Kidney disease
affects as many as 26 million people.

Albumax has recently approved by Medicaid
in New York!

The approval is significant in that it
allows for Medicaid reimbursement of costs for eligible patients using
Albumax. Medicaid is the largest source of funding for medical and
health-related services for people with limited income.

Make sure you put MVSR on your watch list,
because at it’s current dirt cheap price, I believe it’s bargain!!!

Do your own research on MVSR, but do it
fast as it could rally along with this market.

MVSR realizes that
the healthcare sector is one of the most lucrative in the world!

Who doesn’t need healthcare?

U.S. health care spending alone is expected to reach $4.2 trillion in
2016!

MVSR is a medical communications company dedicated to providing concise
and timely medical information to healthcare industry professionals.

When pharmaceutical companies need to increase prescription volume and
boost sales for primary and secondary brands, MVSR is the company that can
extend the reach beyond the company’s sales representatives’ territory and
dramatically expand the target’s audience.

MVSR exclusively serves the bioscience and pharmaceutical markets,
offering specialized medical marketing consulting, graphic design, web
site marketing strategy, event management, public relations and market
research.

Currently the global market for biotechnological drugs is $460 billion!

With the industry spending over $14 Billion annually on detailing, there
is increased pressure on pharmaceutical companies to find new, profitable
techniques for reaching physicians and building revenues.

From pre-product development through product launch and commercialization,
MVSR offers worldwide experience in delivering effective and successful
integrated marketing and creative communications campaigns for the mutual
benefit of both pharmaceutical vendors as well as the practitioners.

But, remember, MVSR is not a manufacturer or producer of any drug. MVSR
specializes in the sales and marketing of these drugs. Also, the physician
communication and presentations.

MVSR is able to make profits by cutting deals with the actual
manufacturers.

MVSR cost-effectively reaches the full spectrum of physicians who will
find it easy and convenient to learn about a company’s pharmaceutical
products.

It has been said that within the next 5 to 10 years, over 76 million baby
boomers are scheduled to retire from the workforce.

With this kind of number, there will be a great demand for pharmaceutical
drugs!

MVSR has signed an agreement giving MVSR the exclusive right to distribute
Albumax in Italy.

Albumax, a whey protein isolate formula, makes it easy for Kidney disorder
patients to reach their daily requirements of high quality protein in
their diet.

MVSR anticipates consummating a distribution relationship in Italy
shortly.

According to the National Kidney Foundation, 26 million Americans have
Chronic Kidney Disease (CKD) and another 20 million more are at increased
risk!

According to The Kidney Alliance, a UK organization and sponsor of World
Kidney Day, worldwide, more than 500 million people are living with some
form of kidney disease!

Albumax has been approved by the New York State Medicaid Office. Albumax
has been approved under code B4155 as an enteral product. The approval is
significant in that it allows for Medicaid reimbursement of costs for
eligible patients using Albumax.

Medicaid is the largest source of funding for medical and health-related
services for people with limited income.

MVSR CEO Mr. Dino Luzzi said, "Medicaid approval is an extremely important
component in our marketing initiative for the national launch of Albumax.
Medicaid acceptance for Albumax certainly strengthens the interest in the
product, and increases the willingness of providers and patients to use
Albumax to increase blood albumin levels in kidney disorder patients."

MVSR has also signed a revenue sharing agreement for the marketing and
sale of LIPIDEME(tm)
with PanGenex Corporation.

PanGenex is a publicly traded corporation that pursues business
opportunities in the $70 billion nutraceutical and dietary supplement
industry.

The terms of the Agreement call for MVSR and PanGenex to pool collective
resources for the marketing and sale of LIPIDEME(TM), a synergistic blend
of ingredients designed to lower cholesterol four ways.

The American Heart Association estimates that nearly 140 million Americans
have either borderline-high or high!

In 2003, approximately 22 million people took a medication to try to lower
their cholesterol.

MVSR CEO Dino Luzzi stated, "We are very pleased that PanGenex has
selected Medivisor to market and sell LIPIDIME. Under this agreement our
main objective will be to contribute to the sales growth of LIPIDIME
through both US and International distribution channels. This will also
drive further revenue and profits for Medivisor."

Make sure MVSR is on your watch list, if the market rallies hard MVSR
could follow!

MVSR is working in a very profitable
industry.

The global pharmaceuticals market was estimated at estimated at $554
billion in 2004!

With the industry spending over $14 billion annually on detailing, there
is increased pressure on pharmaceutical companies to find new, profitable
techniques for reaching physicians and building revenues

This is where MVSR comes in.

MVSR does not manufacture any drugs, but they focus on the sales and
marketing of drugs to physicians.

This is actually better than be a
pharmaceutical company.  If a bio company has only 1 drug product and that
drug fails in clinical trials the whole company could fail!

Pharmaceutical companies can use MVSR from pre-product development through
product launch and commercialization.

MVSR specializes in medical marketing consulting, graphic design, web site
marketing strategy, event management, public relations and market
research.

MVSR offers worldwide experience in delivering effective and successful
integrated marketing and creative communications campaigns for the mutual
benefit of both pharmaceutical vendors as well as the practitioners.

MVSR knows that physicians play a very important role in pharmaceutical
sales. They decide what to prescribe to their patients.

MVSR cost-effectively reaches the full spectrum of physicians who will
find it easy and convenient to learn about a company’s pharmaceutical
products.

Through e-detailing, MVSR provides physicians presentations of different
pharmaceutical drugs.

Physicians just have to log into MVSR’s website to view the presentations.

To view a power point representation and see how MVSR works, click here:
http://medivisor.com/pharma_pres.html

MVSR has signed several agreements that could lead to huge profits in the
future, including a a revenue sharing agreement for the marketing and sale
of LIPIDEME(tm)
with PanGenex Corporation.

PanGenex is a publicly traded corporation that pursues business
opportunities in the $70 billion nutraceutical and dietary supplement
industry.

The terms of the Agreement call for MVSR and PanGenex to pool collective
resources for the marketing and sale of LIPIDEME(tm),
a synergistic blend of ingredients designed to lower cholesterol four
ways.

The American Heart Association estimates that nearly 140 million Americans
have either borderline-high or high!

In 2003, approximately 22 million people took a medication to try to lower
their cholesterol.

MVSR CEO Dino Luzzi stated, "We are very pleased that PanGenex has
selected Medivisor to market and sell LIPIDIME. Under this agreement our
main objective will be to contribute to the sales growth of LIPIDIME
through both US and International distribution channels. This will also
drive further revenue and profits for Medivisor."

MVSR intends to increase awareness for LIPIDEME(TM) in Italy. Since
signing the initial revenue sharing agreement with PanGenex Corporation,
Medivisor has gathered initial interest for the product and expects to
begin shipping samples later in the month.

MVSR also wants to tap into the billion dollar
energy drink sector.

MVSR intends to begin marketing its own targeted energy drink initially
throughout the European continent.

The energy drink market is one of the trendiest and fastest growing
segments within the overall beverage market.

According to Market Research Group, the energy drink category has grown by
440% since 2002 to a whopping $6.6 billion in 2007 and is expected to
reach $9 billion in 2011!

MVSR’s yet to be named product will be launched in Italy within the shot
category of the energy drink market.

The shot category is experiencing tremendous growth due to the fact that
at only two ounces, you get more energy and have less to drink than with
the larger canned competitors.

MVSR CEO Dino Luzzi said, "We look to set this product apart from the
competition by including a formula blend with Acai. Recently, the
remarkable health benefits of Acai have been validated by modern science.
Because of its superior nutrient content and unparalleled antioxidant
levels, Acai is now widely regarded as one of the world’s top superfoods."

(Information Source: BlueWave)

For more information on
MVSR, visit their website at:

http://www.medivisor.com

FDA APPROVED
Mucotrol(tm):
Concentrated Oral Gel Wafers

The National Cancer Institute estimates that
approximately 300,000 cancer patients in the U.S. suffer from Mucositis
(oral lesions) associated with cancer treatments.
Mucotrol(tm)
is the FIRST and
ONLY concentrated oral gel wafer to
target painful mouth soars and provide immediate, long-lasting relief.

When
dissolved in the mouth, Mucotrol(tm)
forms a coating on the oral mucosal surface, thereby soothing oral lesions
that may be caused by chemotherapy or radiation.

Mucotrol(tm)
is formulated as a slow dissolving
wafer, and unlike other products offers added convenience as no water is
required by the user.

In addition to usage for chemo
and radiation, Mucotrol(tm)
is also effective in the treatment of irritation due to oral surgery,
traumatic ulcers caused by braces, ill-fitting dentures, or disease.

Treating pain from illness and
disease generates $BILLIONS in sales
for profit-rich Pharmaceutical and Bio-science Companies every year. This
is a huge market as it falls under the behemoth category of pain
management and pain relief.

Now that
Mucotrol(tm), a sugar-free oral soluble wafer that dissolves
in the mouth to relieve pain, could be used by more than 1,000,000 people
when combining all the categories for its effective uses,,,

Company
Information

Medivisor, Inc.
326 Walt Whitman Rd.
Huntington Station, NY 11746

http://www.medivisor.com

State Of
Incorporation:  DE
Company
Officers

Dino Luzzi, COO
Prudence Ferrone, Secretary
Wayne Wertheim, Vice President, Secretary

SEC
Reporting Status:  SEC Reporting Company

Estimated
Market Cap:  $3,980,540 as of Sep 25, 2008

Outstanding Shares:  13,726,000 as of Apr 17, 2008

Authorized Shares:  100,000,000 as of Apr 16, 2008

About Medivisor Inc.

Medivisor
is a medical communications company dedicated to providing concise and
timely medical information to healthcare industry professionals. Medivisor
exclusively serves the bioscience and pharmaceutical markets, offering
specialized medical marketing consulting, graphic design, web site
marketing strategy and market research.

About Cura
Pharmaceutical: Cura is a privately held pharmaceutical business that
develops, distributes and sells innovative and generic pharmaceuticals. It
focuses on selected niche specialty markets through the offering of
distinctive products and services, which provide distinct unmet medical
needs.

About
Mucotrol(TM): Mucotrol(TM) is prescribed for the management and relief of
pain for Mucositis, which may be caused by chemotherapy or radiotherapy
and irritation due to oral surgery. The National Cancer Institute
estimates that approximately 300,000 cancer patients in the U.S. suffer
from mucositis associated with cancer treatments.

Mission Statement

The primary reason
why medical vendors and pharmaceutical companies desire access to medical
professionals is to have the healthcare professionals use their
service/product or refer patients to use their service/product. Product
detailing often makes up to 60-70% of the total promotional budget.

Medical sales and
medical communication relies on the ability to get in front of medical
professionals, either during practice hours, or via an invitation to a
presentation at an outside location. There is little control over the
environment and the process. Medivisor will provide an internet venue
where vendors can "detail’ and clinicians can absorb presented
information, at time frames, and locations convenient to both, with
availability 24/7/365. This allows the professional to choose a setting
and time where their interest and attention level is high and focused.
Medivisor will provide appropriate honorariums to respect and recognize
the time the professional spent during the presentation.

Medivisor will seek
to meet the growing need to inform medical professionals on advances in
medicine, and changes within the industry at internet speed by providing a
one-stop location to access information, education, tools, and resources
anywhere and any time. Medivisor will include the use of advanced, cutting
edge technology to create a variety of educational and informational
presentations online, to the mutual benefit of both the pharmaceutical
vendors as well as the practitioners.

Your
company needs to increase prescription volume and boost sales for
primary and secondary brands. But with physicians growing less and less
receptive to detail sales force efforts and direct mail communications,
detail time is dropping and cost-per-prescription marketing expenditures
are going up. You need to solve this marketing challenge to meet your
marketing and sales goals,,,But how?

With e-detailing
from Medivisor, pharmaceutical companies generate increased sales with
lower costs, offering a higher ROI from your branding and sales efforts.
Medivisor.com offers a strategic platform to reach physician prescribers
with your customized product presentation. Most important, with an
ever-growing number of physicians now online, your brand/product
communications will be viewed on Medivisor’s user-friendly website when
physicians are most receptive to your message-when they want it [often
after hours] and where they want it [often at home].

Office Hours 28%

Weekends 34%

Before 8 a.m. 4%

After 5 p.m. 34%

Enhance Physician Market Penetration

Now you can
cost-effectively reach the full spectrum of physicians who will find it
easy and convenient to learn about your pharmaceutical products through
Medivisor.com. Medivisor will extend your reach beyond your sales
representatives’ territory and dramatically expand your target
audience,,,with a focus on the untapped market. From large volume
prescribers to physicians in vacant territories, your Medivisor
e-detailing presentation maximizes prescribers’ prescription potential,,,
at a significantly lower cost!

Medivisor targets:

High and Low
Prescribers
Geographically
Non-Targeted
Geographically
Difficult-to- See

Non-Targeted
Geographical Prescribers

Large Volume Busy
Practice, Hard-to-See Practitioners

Reach Physicians With Your Vital Product
Information

Medivisor enhances
physician communication, providing your latest drug information to
thousands of physicians.

New Product Introductions
,,,building drug adoption

New Indications
,,,increasing
product usage
New Clinical Study Results
,,,communicating findings

Label Changes
,,,assuring
compliance

Client List

Increase Profitability

Medivisor can help
to reduce your sales and marketing expenditures while supporting your
sales force. With the industry spending over $14 Billion annually on
detailing, there is increased pressure on pharmaceutical companies to find
new, profitable techniques for reaching physicians and building revenues.
Medivisor e-detailing can be a solution to increased bottom-line profits.

Supporting Your Sales Force While Saving
Costs

Medivisor augments,
supplements and enhances the efforts of your sales force. Your sales force
[or Medivisor] distributes coded invitations to physicians to join your
customized presentations on Medivisor. Your Medivisor presentation will
generate requests for drug samples and sales rep visits, changing the
office encounter from a "push"
to a "pull. Medivisor generates more quality details to optimize your
field sales force efficiency.

Reduces the
cost of each detail visit

Generates more
prescription
Gives sales reps
reason to visit physician
Complements
traditional advertising at significantly lower cost

Provides
reductions in low priority budget areas

Sales reps
spend less time traveling

By being in the
forefront of technology, your pharma company will benefit by cost-savings,
additional product sales, and increased ROI.

Our e-Solutions Empower You ,,, With
Feedback And Market Intelligence

Pharma companies
presenting on Medivisor are able to make timely presentations and receive
immediate results and product feedback from physicians. After
participating in your Medivisor presentation, physicians complete their
honorarium. You get real-time feedback and market intelligence.
Questionnaires are customized to include physician demographics, practice
profile, brand prescribing data and more. Physicians will receive
appropriate honoraria based on your program parameters.

Now is the time to start your e-detailing
program.

With Medivisor; You Will:

Reach Thousands of
Physicians With Your Message

Communicate With
Hard-To-See Physicians
Engage Physicians
Through User-Friendly Website

Access Your Target
Audience When They Are Most Receptive

Disseminate Important
Brand/Product Information

Heighten Awareness of
Product/Clinical Information

Receive Immediate
Physician Feedback
Reduce Sales Costs While
Increasing Revenues
Increase Sales Force
Penetration
Build Reach and
Frequency of Branding Message

Reach Non-Physician
Prescribers, HMO’s and Large Medical Communities

Gain an Edge Over Your
Competition

Company News

Albumax Has Been
Approved by Medicaid in California & Pennsylvania
Marketwire (Thu, Sep 25)

Medivisor, Inc.
Receives Initial Purchase Order Marketwire (Wed, Sep 24)

Medivisor, Inc. in
Negotiations With Distributor for Energy Drink Marketwire (Mon,
Sep 22)

Medivisor Inc.
Announces Exclusive Distribution Rights in Italy for Albumax
Marketwire(Thu, Sep 18)

Medivisor Inc.
Announces Update on LIPIDEME(TM) Marketwire (Tue, Sep 16)

Albumax Has Been
Approved by Medicaid in New York Marketwire (Fri, Sep 12)

Medivisor, Inc. to
Market Energy Drink Marketwire (Wed, Sep 10)

Medivisor Inc. to
Market Albumax Marketwire (Fri, Sep 5)

Medivisor Inc.
Signs Revenue Sharing Agreement With PanGenex Marketwire (Wed,
Sep 3)

For more information
visit content source 
http://www.medivisor.com

Disclaimer Release
Of Liability:
This email (WillyWizard.com L.L.C.) does contain paid advertisement from
time to time. Some listed companies in this email
should be considered paid image advertisement on behalf of the Companies, IR Firms or non affiliated third party whose articles and/or information
might appear herein and may not be construed as investment advice. All
paid image marketing advertisement or consulting services listed by
WillyWizard.com L.L.C.. are
listed within this disclaimer. No analysis has been made by the Publisher
of the financial position, condition, business, and other factors about
the Company(s), which may appear in the advertisements contained herein.
The information contained herein is based upon sources, which may be
consider reliable but is not guaranteed by WillyWizard.com L.L.C. or
officers, directors, employees or any affiliated parties. Any sales and/or
earnings forecasts were obtained by and/or from audited financials and/or
news releases and unless otherwise stated are not endorsed by the
management of the company which is the subject matter of this
advertisement. From time to time The Publisher will write a commentary
within this newsletter and the commentary should not be construed as
investment advice but the opinion of The Publisher. The Publisher,
therefore, makes no guarantee as to the reliability of such information.
Statements in this publication are made as of the date stated and are
subject to change without notice. The image marketing advertisements
are not a solicitation to purchase, hold, or dispose of shares warrants or
options of an advertising Company(s) or IR Firm(s). All corporate image
profiles are for the sole purpose of corporate image marketing only.
Readers should consult with their own independent tax, business and
financial advisors with respect to any investment opportunity, including
any contemplated investment in the advertised Company(s). All information
concerning a Company advertising herein and contained in this website
should be verified independently with such company and an independent
securities analyst. The
Publisher has been paid one thousand dollars by BlueWave Advisors, LLC for one week MVSR advertisement at WillyWizard.com. The
Publisher doesn’t own any stock mentioned in this email at this time. If the Publisher
does take a position

The Publisher will therefore benefit from
any increase in share price as to the stock owned. The Publisher may increase or decrease its ownership interest
in the Company at any time before, during or after the distribution of any
paid or non paid image advertisement. The Publisher may profit in the
event the shares of any Company profiled by this newsletter increase in
value. These positions may be liquidated from time to time even after we
have made positive comments regarding the Company. The owner of this
newsletter does reserve the right to buy, sell or hold company stock of
companies listed within this newsletter. The owner also reserves the right
to trade listed company’s stock multiple times per day without notice to
readers. Never invest in any stock featured within this newsletter unless
you can afford to lose your entire investment. This disclaimer releases
the publisher from all liabilities for any losses a reader my incur.
Section 17 of the Securities Act of 1933, which covers Fraudulent
Interstate Transactions  and specifically 17-(b) which reads as follows:
"Use of interstate commerce for purpose of offering for sale. It shall be
unlawful for any person, by the use of any means or instruments of
transportation or communication in interstate commerce or by the use of
the mails, to publish, give publicity to, or circulate any notice,
circular, advertisement, newspaper, article, letter, investment service,
or communication which, though not purposing to offer a security for sale,
describes such security for a consideration received or to be received,
directly or indirectly, from an issuer, underwriter, or dealer, without
fully disclosing the receipt, whether past or prospective, of such
consideration and the amount thereof" SAFE HARBOR FOR FORWARD-LOOKING
STATEMENTS Except for historical information contained herein, the
statements on this website and newsletter are forward-looking statements
that are made pursuant to the safe harbor provisions of the Private
Securities Reform Act of 1995. Forward-looking statements involve known
and unknown risks and uncertainties, which may cause a company’s actual
results in the future periods to differ materially from forecasted
results. These risks and uncertainties include, among other things,
product price volatility, product demand, market competition and risk
inherent in the companies operations. You can identify these statements by
the fact that they do not relate strictly to historical or current facts.
They use words such as “anticipate,” “estimate,” “expect,”
“project,” “intend,” “plan,” “believe,” and other words and terms
of similar meaning in connection with any discussion of future operating
or financial performance.

=A9

2007 WillyWizard.com L.L.C